GLP1 medications and metabolic health: a clinical guide

Preventive medicine is undergoing a profound shift. Weight alone is no longer the metric that matters most: what actually measures real health is liver fat, systemic inflammation, and insulin sensitivity. And GLP1 medications, which have rapidly evolved from diabetes treatments to general metabolic health tools, are redefining what is possible. In this conversation, Dr. Mauricio González, a triple board-certified internal medicine and obesity medicine physician, explains what everyone should know.

The minimum effective dose as a guiding principle

One of Dr. González's central ideas is the concept of minimum effective dose, applied not just to medications but to everything: exercise, nutrition, sleep. In the real world, where people have jobs, families, and packed schedules, knowing what is enough matters as much as knowing what is optimal. Two resistance training sessions per week, twenty to thirty minutes of cardio per session, and a diet rich in fiber and lean protein are foundations that most people can actually sustain over the long term.

Metabolic health beyond weight

One of the most important paradigm shifts in medicine is that health is no longer evaluated by weight or BMI alone. The new parameters include:

• A1C and fasting glucose: markers of glycemic control
• High-sensitivity C-reactive protein: indicator of systemic inflammation
• FIB-4: a formula calculated from standard blood tests that helps diagnose the presence of liver fat
• Triglycerides and liver enzymes (ALT/AST): early signals of metabolic liver damage

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 70% of people with type 2 diabetes, and it can be reversed. At this stage, the liver is not permanently damaged: it is simply accumulating fat. When detected early and addressed with dietary changes, exercise, alcohol reduction, and when appropriate, medication, progress can be significant within months.

What GLP1 medications are and how they work

GLP1 receptor agonists are medications that act on appetite centers in the brain, slow gastric emptying, and improve insulin sensitivity. The best known are semaglutide (Wegovy for obesity, Ozempic for diabetes) and tirzepatide (Zepbound, Mounjaro), which adds a second mechanism of action (GIP agonism) and delivers greater weight loss.

Oral forms are also now available: oral semaglutide and orforglipron, the first non-peptide GLP1, which requires no refrigeration and no fasting before taking it. These options make treatment more accessible for those who prefer not to inject.

How to choose the right medication

The decision depends on several factors:

• If there is obstructive sleep apnea, tirzepatide (Zepbound) has specific evidence
• If there is a history of cardiovascular disease, semaglutide has FDA approval for secondary prevention
• If the patient wants a more affordable or easier-to-take option, oral forms are viable alternatives
• If the target is only ten to twelve percent weight loss, newer oral GLP1s may be sufficient

The importance of nutrition on GLP1 treatment

One of the most striking clinical findings Dr. González shares is that patients on GLP1 medications adopt healthier diets almost automatically: they go from eating eighteen grams of fiber per day to forty grams, not because they are told to, but because the body craves it and they feel better. This window of motivation is the best opportunity to establish lasting habits.

His recommendations for patients on GLP1:

• Prioritize fiber: vegetables, legumes, whole grains, fruit. Fiber reduces gastrointestinal side effects and improves the lipid profile
• Lean protein: tofu, fish, chicken, egg whites, Greek yogurt
• Healthy fats: olive oil, walnuts, almonds, avocado
• Active hydration: GLP1 can suppress the sense of thirst; drinking at least two liters of water per day prevents dehydration and constipation

Supplements with evidence

Dr. González's approach to supplements is pragmatic: positive, reasonable, or neutral.

• Creatine monohydrate: positive. Improves strength training performance and muscle synthesis, especially useful for people losing weight who want to protect muscle mass
• Vitamin D: positive in people with deficiency, especially those with prediabetes or during pregnancy
• Multivitamin: reasonable. Obesity populations have a higher prevalence of micronutrient deficiencies
• Omega-3: more reasonable for people who do not eat oily fish regularly; useful if triglycerides are elevated

The psychology of treatment

A pattern Dr. González sees frequently: patients who stop their GLP1 because of guilt. If I need medication to be healthy, something is wrong with me. His usual response: no one feels guilty for using an inhaler for asthma or an antihypertensive for blood pressure. Obesity is a neuroendocrine disease rooted in the central nervous system, not a character flaw. This argument works about half the time; the other half still feels the urge to prove they can do it without medication.

A patient-centered paradigm

The key to everything, according to Dr. González, is long-term accompaniment. With proper coaching, many patients do not need maximum doses of GLP1 to get good results. A Danish telemedicine company showed that with intensive lifestyle coaching, the average semaglutide dose was only one milligram per week, with weight loss of fourteen to fifteen percent. Combining medication at lower doses, quality nutrition, and regular resistance training produces results that are both sustainable and profound.